Edition:
United States

AnGes Inc (4563.T)

4563.T on Tokyo Stock Exchange

840JPY
21 Jul 2017
Change (% chg)

¥70 (+9.09%)
Prev Close
¥770
Open
¥785
Day's High
¥840
Day's Low
¥770
Volume
29,171,500
Avg. Vol
6,445,948
52-wk High
¥844
52-wk Low
¥214

Latest Key Developments (Source: Significant Developments)

Anges MG says exercise of options
Monday, 12 Jun 2017 02:08am EDT 

June 12 (Reuters) - Anges MG Inc <4563.T>:* Says 20,000 units of its 29th series options were exercised to 2 million shares of its common stock from June 10 to June 12.* Says the shares were exercised at the price of 390 yen per share.  Full Article

Anges expects to apply for approval to manufacture treatment for severe blockage of the arteries in the legs - nikkei
Friday, 9 Jun 2017 04:16pm EDT 

June 9 (Reuters) - Anges Mg Inc <4563.T>:Anges expects to apply in October for approval to manufacture and market treatment for severe blockage of the arteries in the legs - Nikkei.  Full Article

Anges MG announces exercise of options through private placement
Friday, 9 Jun 2017 02:48am EDT 

June 9(Reuters) - Anges MG Inc <4563.T>:Says 12,500 units of its 29th series options were exercised to 1.3 million shares of its common stock from June 1 to June 9, through private placement.  Full Article

Anges MG announces exercise of options
Wednesday, 31 May 2017 04:18am EDT 

May 31(Reuters) - Anges MG Inc <4563.T>:Says 8,500 units of its 29th series options were exercised to 850,000 shares of its common stock from May 24 to May 31, through private placement.Says 17,500 units of its 29th series options were exercised to 1,750,000 shares of its common stock in May .  Full Article

Anges MG receives IND approval from FDA
Monday, 24 Apr 2017 11:15pm EDT 

April 25 (Reuters) - Anges MG Inc <4563.T>:* Says it received investigational new drug (IND) approval from FDA, for a clinical trial with F-kappaB decoy oligo DNA in U.S, for treatment of discogenic lower back pain.  Full Article

AnGes MG plans cooperation with Vical Inc on development of genetic medication for Chronic Hepatitis B
Tuesday, 4 Apr 2017 04:06am EDT 

AnGes MG Inc <4563.T> :Says co enters into a cooperation contract with a US-based firm Vical Incorporated, on joint development of genetic medication for treatment of Chronic Hepatitis B.  Full Article

AnGes MG to change name to AnGes Inc
Monday, 20 Feb 2017 01:00am EST 

AnGes MG Inc <4563.T>: Says it plans to change its name to AnGes Inc .Says the change will effective on July 1.  Full Article

AnGes MG signs strategic business alliance agreement with Vical
Thursday, 8 Dec 2016 03:17am EST 

AnGes MG Inc <4563.T>:Says it signed strategic business alliance agreement for DNA vaccine, with Vical Inc on Dec. 8.  Full Article

Medikit and AnGes MG agree to terminate joint development contract
Tuesday, 6 Dec 2016 02:00am EST 

Medikit Co Ltd <7749.T>:Says the co and AnGes MG Inc <4563.T> agree to terminate joint development contract for NF-κB decoy oligo-coated PTA balloon catheter for dialysis shunt.  Full Article

AnGes MG announces exercise of 10,300 options
Wednesday, 28 Sep 2016 02:00am EDT 

AnGes MG Inc <4563.T> :Says 10,300 of 28th warrants were exercised into 1.03 million shares of its common stock from Sept. 26 to Sept. 28, including 150,000 shares at exercise price 258 yen, 200,000 shares at 242 yen and 680,000 shares at 234 yen per share.  Full Article

BRIEF-AnGes submits CTN of hypertension DNA vaccine

* Says it submitted Clinical Trial Notification (CTN) of hypertension DNA vaccine to Therapeutic Goods Administration (TGA) in Australia